ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2008

Jun 3, 2008

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity LIVING CELL TECHNOLOGIES LTD ABN 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MR DAVID COLLINSON
Date of last notice	13 FEBRUARY 2007

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	DIRECT and INDIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	29 MAY 2008
No. of securities held prior to change	188,790 ORINARY SHARES (HELD BY DAVID COLLINSON) 10,149,090 ORDINARY SHARES (HELD BY DAVID AND GRAEME COLLINSON) 60,494 ORDINARY SHARES (HELD BY DAVID COLLINSON, GRAEME COLLINSON AND ANNA NATHAN) 2,123,300 OPTIONS EXPIRING 30/06/2010 350,000 OPTIONS EXERCISABLE AT $0.30 PER SHARE, VESTING ON 9 MARCH 2007 AND EXPIRING ON 9 MARCH 2009 104,166 ORDINARY SHARES (HELD BY PANCELL LIMITED)
Class	ORDINARY SHARES
Number acquired

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed	39,562
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.350245 EACH
No. of securities held after change	149,228 ORINARY SHARES (HELD BY DAVID COLLINSON) 10,149,090 ORDINARY SHARES (HELD BY DAVID AND GRAEME COLLINSON) 60,494 ORDINARY SHARES (HELD BY DAVID COLLINSON, GRAEME COLLINSON AND ANNA NATHAN) 2,123,300 OPTIONS EXPIRING 30/06/2010 350,000 OPTIONS EXERCISABLE AT $0.30 PER SHARE, VESTING ON 9 MARCH 2007 AND EXPIRING ON 9 MARCH 2009 104,166 ORDINARY SHARES (HELD BY PANCELL LIMITED)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON MARKET SALE

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002